ZURA — Zura Bio Ltd
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1855644 ·
Last close
$4.13
Market Cap
$395.77M
52W High
$7.44
52W Low
$3.15
ADV30
1,852,537
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -29,321,000 | -26,304,000 | 213,403,000 | 205,134,000 | 16,318,000 |
| Mar 2026 | 0 | — | -25,499,000 | -24,223,000 | 228,641,000 | 225,594,000 | 11,745,000 |
| Dec 2025 | 0 | — | -18,411,000 | -17,175,000 | 113,948,000 | 109,407,000 | 12,410,000 |
| Sep 2025 | 0 | — | -19,519,000 | -18,040,000 | 143,935,000 | 139,017,000 | 25,491,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-72,675,000
Investing CF
$-77,000
Financing CF
$127,777,000
CapEx
$-77,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.79
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-248,770,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-81,491,000
Pretax Income TTM
$-75,431,000
Interest Exp TTM
—
Analysts
6
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -75,246,000 | -68,650,000 | 113,948,000 | 12,410,000 | 101,538,000 | -64,815,000 |
| Dec 2024 | 0 | -55,189,000 | -52,403,000 | 179,533,000 | 19,514,000 | 146,815,000 | -28,076,000 |
| Dec 2023 | 0 | -62,638,000 | -60,360,000 | 100,843,000 | 21,292,000 | 59,330,000 | -15,054,000 |
| Dec 2022 | 0 | -27,162,000 | -25,738,000 | 5,262,000 | 27,318,000 | -32,056,000 | -1,202,000 |
TTM Snapshot
Revenues TTM
$-5,838,000
NetIncome TTM
$-75,431,000
OpCashFlow TTM
—
Assets (Latest)
$228,641,000
Forward EPS
$-0.58
Max Pain — expiry 2026-12-18
max pain strike: $5.00 · spot: $4.00 · call oi: 2,580 · put oi: 1,182
Expected Move to 2026-12-18:
±$4.70
(117.50%) —
implied range
$-0.70 –
$8.70
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| EIKN | Eikon Therapeutics, Inc. | $406.24M | $7.50 | — |
| KYTX | Kyverna Therapeutics, Inc. | $382.19M | $6.18 | — |
| FENC | FENNEC PHARMACEUTICALS INC. | $372.76M | $10.63 | — |
| SCTX | Scribe Therapeutics, Inc. | $364.06M | $19.23 | — |
| ENTX | Entera Bio Ltd. | $432.85M | $2.50 | — |
News headlines (Yahoo Finance, 1h cache)
This biotech stock is a top pick at Guggenheim
2026-10-07 08:00 · Yahoo
Zura Bio to Participate in the Cantor Global Healthcare Conference
2026-08-31 20:30 · Yahoo
Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-08-21 23:57 · Yahoo
Here's Why We're Not Too Worried About Zura Bio's (NASDAQ:ZURA) Cash Burn Situation
2026-06-03 10:09 · Yahoo
One Zura Bio Insider Raised Their Stake In The Previous Year
2026-04-23 10:06 · Yahoo
Zura Bio (ZURA) Hits Enrollment Milestones As Losses Widen Sharply
2026-09-11 05:35 · Yahoo
Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program
2026-06-29 11:30 · Yahoo
Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates
2026-08-11 11:30 · Yahoo
William Blair Starts Zura Bio (ZURA) at Outperform
2026-07-14 18:09 · Yahoo
Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million
2026-02-25 20:26 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.